Company Overview of Clearside BioMedical, Inc.
Clearside BioMedical, Inc., an ophthalmic company, specializes in the research, development, and commercialization of therapeutic products through an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as retina, trabecular meshwork, and corneal stroma. The company’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space. Clearside BioMedical was incorporated in 2011 and is based in Atlanta, Georgia.
Founded in 2011
Key Executives for Clearside BioMedical, Inc.
Chief Executive Officer and President
Executive Vice President of Research and Development
Vice President of Research and Development
Compensation as of Fiscal Year 2014.
Clearside BioMedical, Inc. Key Developments
Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment
Mar 2 15
Clearside Biomedical, Inc. announced the enrollment of the first patient in a Phase 2 randomized, controlled, masked, multi-center clinical trial for the treatment of macular edema associated with retinal vein occlusion (RVO) using Clearside's proprietary formulation of triamcinolone acetonide, CLS-TA, administered via suprachoroidal (SCS) injection using Clearsideâ s proprietary microinjector. Approximately 40 patients will be enrolled at 10 sites in the United States for the Phase 2 clinical trial. All patients will receive one intravitreal injection of Eylea and will be randomized on a 1:1 basis to receive a suprachoroidal injection of either CLS-TA or a sham procedure in the same visit. After randomization, patients will be seen in the clinic once per month for three months. Patients in either treatment arm will be evaluated at the subsequent visits one-, two- and three-months after the initial assigned treatment to receive additional intravitreal injections of Eylea, if they continue to experience macular edema or reductions in visual acuity. If they do not experience increases in macular edema or reductions in visual acuity at these subsequent visits, they will not receive additional intravitreal Eylea treatments. The primary objective of this study is to determine if a single suprachoroidal injection of CLS-TA administered along with an intravitreal injection of Eylea, compared to a single intravitreal injection of Eylea alone, will decrease the need for additional intravitreal Eylea treatments over three months.
Clearside BioMedical, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015
Dec 15 14
Clearside BioMedical, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.
Clearside BioMedical, Inc. Presents at Nomura Biotechnology Conference, Nov-06-2014 10:00 AM
Oct 22 14
Clearside BioMedical, Inc. Presents at Nomura Biotechnology Conference, Nov-06-2014 10:00 AM. Venue: The Mandarin Oriental Hotel, 776 Boylston Street, Boston, MA 02199, United States. Speakers: Glenn Noronha, Executive Vice President of Research and Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 29, 2014
April 28, 2014